10/31/14 IG 9.81 IGI Laboratories $IG Hit a 52 week high of

New Post Public Reply Private Reply Replies (0) Message Board

Nov 2, 2014 at 1:32 AM

10/31/14 IG 9.81 IGI Laboratories $IG Hit a 52 week high of 10.49 Closing the day 10/31/14 at 9.81 -0.15 -1.51% With a day low of 9.76 and a total volume of 828,300.

IG Recent Posts: http://investorshangout.com/Igi-Laboratories-IG-56758/

IG IGI Laboratories Recent Headline News

Strength Seen in Cempra (CEMP): Stock Rises 10.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:25AM CDT
Cempra (CEMP) was a big mover last session, with shares rising over 10% on the day.
LCI: 56.72 (+0.83), ADHD: 3.62 (-0.05), CEMP: 13.60 (-0.09), IG: 9.81 (-0.15)

Synergy Pharmaceuticals, Inc. (SGYP) Surges: Stock Rises 10% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 8:11AM CDT
Synergy Pharmaceuticals, Inc. (SGYP) was a big mover last session, as the company saw its shares rise 10% on the day.
SGYP: 3.43 (-0.15), ADHD: 3.62 (-0.05), IG: 9.81 (-0.15), BIOD: 1.55 (+0.02)

Receptos (RCPT) Worth Watching: Stock Moves Up 41.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 8:39AM CDT
Receptos, Inc. (RCPT) was a big mover last session, as its shares rose over 41% on the day.
LCI: 56.72 (+0.83), PTLA: 28.50 (+0.15), RCPT: 103.65 (+1.93), IG: 9.81 (-0.15)

Strength Seen in Zafgen (ZFGN): Stock Adds 7.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 7:51AM CDT
Zafgen, Inc. (ZFGN) was a big mover last session, as its shares rose over 7% on the day.
LCI: 56.72 (+0.83), ZFGN: 21.30 (-0.04), PTLA: 28.50 (+0.15), IG: 9.81 (-0.15)

Should IGI, Laboratories (IG) Be On Your Radar Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 7:47AM CDT
IGI, Laboratories has been overlooked by investors but it has actually seen estimates rise over the past month.
IG: 9.81 (-0.15)

IGI Laboratories Inc (IG) Upgraded From Hold to Buy
at The Street - Tue Oct 28, 8:38AM CDT
IGI Laboratories Inc (IG) has been upgraded by TheStreet Ratings from Hold to Buy with a ratings score of B.
IG: 9.81 (-0.15)

NanoViricides (NNVC) Jumps: Stock Adds 9.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 8:04AM CDT
NanoViricides, Inc. (NNVC) was a big mover last session, as the company saw its shares rise over 9% on the day.
ADHD: 3.62 (-0.05), NNVC: 3.81 (-0.01), IG: 9.81 (-0.15), BIOD: 1.55 (+0.02)

Regulus Therapeutics (RGLS) Soars: Stock Rises 6.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 7:51AM CDT
Regulus Therapeutics Inc. (RGLS) was a big mover last session, as its shares rose almost 7% on the day.
LCI: 56.72 (+0.83), PTLA: 28.50 (+0.15), RGLS: 19.96 (+1.66), IG: 9.81 (-0.15)

La Jolla Pharmaceutical Co. (LJPC) Jumps: Stock Rises 10.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 8:32AM CDT
La Jolla Pharmaceutical Co. (LJPC) was a big mover last session, as the company saw its shares rise more than 10% on the day.
LJPC: 10.99 (-0.06), CEMP: 13.60 (-0.09), IG: 9.81 (-0.15), BIOD: 1.55 (+0.02)

IGI Laboratories Announces Third Quarter 2014 Results
PR Newswire - Thu Oct 23, 3:05PM CDT
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based specialty generic pharmaceutical company, announced its financial results for the third quarter ended September 30, 2014.
IG: 9.81 (-0.15)

IGI Laboratories To Hold Conference Call For 3rd Quarter 2014 Results
PR Newswire - Mon Oct 20, 7:00AM CDT
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based specialty generic pharmaceutical company, announced the Company will hold a conference call at 4:15 pm ET on Thursday, October 23, 2014 to discuss the 3rd quarter 2014 results.
IG: 9.81 (-0.15)

IGI Laboratories, Inc. Appoints Steven Koehler To Board Of Directors
PR Newswire - Thu Oct 09, 3:05PM CDT
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey-based specialty generic pharmaceutical company, today announced that it has appointed Steven Koehler to its Board of Directors. Mr. Koehler will serve as the new Chairman of the Company's Audit Committee.
IG: 9.81 (-0.15)

IGI Laboratories, Inc. Acquires Two Products From Valeant Pharmaceuticals
PR Newswire - Wed Oct 01, 7:00AM CDT
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based specialty generic pharmaceutical company, today announced it has acquired two previously marketed ophthalmic drug products, in addition to the right to acquire three additional previously marketed injectable drug products from affiliates of Valeant Pharmaceuticals International, Inc. after the completion of the due diligence process. All of these products have been approved by the FDA as abbreviated new drug applications (ANDAs) or new drug applications (NDAs). According to IMS Health, the current addressable market in the United States for the therapeutic areas that all of these products were previously indicated for is estimated at $38 million as of August 2014.
IG: 9.81 (-0.15), VRX.TO: 149.80 (+2.53)

Can the Uptrend Continue for IGI, Laboratories (IG)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 26, 9:08AM CDT
Can the Uptrend Continue for IGI, Laboratories (IG)?
IG: 9.81 (-0.15)

IGI, Laboratories (IG) Jumps: Stock Up 18.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 26, 7:51AM CDT
IGI, Laboratories, Inc. (IG) was a big mover last session, as the company shares rose over 18% on the day.
LCI: 56.72 (+0.83), ENDP: 66.92 (+0.63), IG: 9.81 (-0.15), HPTX: 24.30 (-0.13)

Market Maker Surveillance Report. IG, CNET, STV, AIXG, MDBX, RGDO, Winning Stocks With Lowest Price Friction For Thursday, September 25th 2014
M2 - Fri Sep 26, 3:29AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4456 companies with "abnormal" market making, 1102 companies with positive Friction Factors and 4256 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Thursday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. IGI Laboratories Inc (NYSE:IG), Chinanet Online Holdings Inc (NASDAQ:CNET), China Digital Tv Holding Co Ltd (NYSE:STV), Aixtron SE (NASDAQ:AIXG), (OTC:MDBX), (NASDAQ:RGDO). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
AIXG: 12.13 (+0.22), STV: 3.94 (-0.11), CNET: 2.10 (-0.01), IG: 9.81 (-0.15), RGDO: 1.02 (-0.02)

Why IGI Laboratories (IG) Stock Hit a One-Year High Today
at The Street - Thu Sep 25, 1:56PM CDT
Shares of IGI Laboratories (IG) soared to a 52-week high of $9.01 on Thursday after the pharmaceutical company announced it had acquired regulatory rights to 18 AstraZeneca AZN drugs.
AZN: 72.94 (+0.34), IG: 9.81 (-0.15)

IGI Laboratories, Inc. Acquires Eighteen Former Products From AstraZeneca
PR Newswire - Thu Sep 25, 7:30AM CDT
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based specialty generic pharmaceutical company, today announced it has acquired the regulatory rights and related documents and records for 18 drug products from AstraZeneca, 17 of which were marketed. The acquisition includes the regulatory rights and documents for 17 injectable products and 1 suppository product. All of these products had been previously approved by the US FDA as abbreviated new drug applications (ANDAs) or new drug applications (NDAs) prior to their discontinuation or withdrawal from the market. According to IMS Health, the current addressable market in the United States for the therapeutic areas that these products were previously indicated for is estimated at $200 million as of May 2014.
IG: 9.81 (-0.15)

Why IGI, Laboratories (IG) Isn't Done Growing Earnings Yet - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 7:42AM CDT
IGI, Laboratories is one such company that might be well-positioned for future earnings growth as the long term growth rate is 15% and looks impressive
IG: 9.81 (-0.15)

Teligent, Inc. (TLGTQ) Stock Research Links

TLGTQ Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innovative Trial Targets Drug Resistance in Lung Cancer

The Battle Against Drug Resistance Heats Up Folks, we're in a never-ending fight here against one of the toughest adversaries out there: lung cancer. And lemme tell ya, when drugs show resistance, it's like trying to punch a ghost. But there’s a fresh wind blowing, as Dr. Bobak Parang steps up to the plate with a $620K grant aimed squarely at tackling drug resistance in...

Eric Dalton: Redefining Homecare with Vision and Strategy

What's Behind Eric Dalton's Continued Recognition? Now, if you told me a healthcare leader’s named 'Visionary of the Year' twice in a row, my first thought isn't 'stretch goals' but 'show me the goods.' And that’s precisely what Eric J. Dalton has done. The Vice President at Angels on Call Homecare isn't just tooting his own horn; he's building a damn symphony in the...

Software Updates Costly: UX Not the Biggest Culprit

Breaking Updates Trump UX Changes Here's the real scoop: software updates that break functionality are setting companies back more than those user experience (UX) tweaks that folks gripe about but usually muddle through. According to a recent LITSLINK study, even three figures that supposedly quantify UX losses turn out to be questionable at best. Real-world Disasters:...

BD's New Liverty™ TIPS Stent: A Game Changer?

Could This Be the Breakthrough for Portal Hypertension? Now, here's something that might just turn a few heads in the medical world. BD has launched their Liverty™ TIPS Stent Graft in the U.S., a move set to shake up the landscape for treating portal hypertension. This isn't just another shiny new gadget—it's a promise of more personalized patient care in a field...

AppGate Rises as 2026 Leader in Digital Risk

AppGate: Forging a Path in Digital Security In a world where cyber threats seem to lurk around every digital corner, snagging the title of a leader in digital risk protection from the SPARK Matrix is no small feat. Let’s dive deep into AppGate’s rise to the top in QKS Group’s 2026 evaluation. What Sets AppGate Apart? AppGate's leadership status isn't some overnight...

McKinsey and Parloa Join Forces on AI Customer Service

AI-Revolutionizing Customer Service: The New Partnership Out of the boardroom and into the trenches, McKinsey joins hands with Parloa, aiming to reshape how enterprises handle customer service through artificial intelligence. Forget all the corporate fluff you've heard before; these guys are dead set on closing the massive gap companies face in deploying AI agents...

Fannie Mae Q3 2026 Earnings Surpass Expectations

An Upward Trend in Fannie Mae's Financials Hold onto your hats—Fannie Mae's swinging into action with hefty third-quarter numbers that'd make most firms drool. The latest figures, disclosed in their 10-Q filing, boast a net income of $4.2 billion for Q3 2026. You heard me right, billion! Now, to a market vet, these aren't digits to scoff at. And as the economy keeps...

BASIS Bellevue Expands with New K-4 Campus

A New Era for Young Learners in Bellevue When a community-driven school like BASIS Independent Bellevue makes a move to expand, it doesn't happen in a vacuum. They're not just building another campus—they're aiming to sculpt the future right here in Bellevue, and boy, do they have a plan. The new Lower School campus opening come Fall 2027 is dedicated to kiddos in...

BetaNXT and Pave Finance Transform Wealth Management

AI Takes Center Stage in Wealth Management You know, it's not every day we see two powerhouses like BetaNXT and Pave Finance buddying up to shake up the financial advisory world. This partnership's all about harnessing AI to give wealth management firms and financial advisors some serious firepower in portfolio planning. BetaNXT, already a big name with its slick...

Getlabs Brings GI Test Kits to Your Doorstep

By Logan Wright Updated Oct 28, 2026 Category News Views 106

Home Testing: A Game Changer for GI Patients Imagine dragging yourself out of bed, managing gut issues, only to face a grueling trip to a lab. It's the last thing a patient with GI symptoms wants. Enter Getlabs and Genova Diagnostics with a welcome shift: a partnership that promises to bring the lab to your doorstep—literally. The Partnership Expansion Getlabs, the...